Background: Many genetic diseases are due to defects in protein trafficking where the mutant protein is recognized by the quality control systems, retained in the endoplasmic reticulum (ER), and degraded by the proteasome. In many cases, the mutant protein retains function if it can be trafficked to its proper cellular location. We have identified structurally diverse correctors that restore the trafficking and function of the most common mutation causing cystic fibrosis, F508del-CFTR. Most of these correctors do not act directly as ligands of CFTR, but indirectly on other pathways to promote folding and correction. We hypothesize that these proteostasis regulators may also correct other protein trafficking diseases.
Background
Many protein trafficking diseases are caused by mutations that cause temperature sensitive misfolding and can be partially corrected by incubation at low temperature (< 30°C) or treatment with high concentrations of osmolytes such as glycerol, trimethylamine oxide or 4-phenylbutyrate [1] [2] [3] . However, most of these are not feasible therapeutic strategies. Small molecule correctors have recently been identified for several protein trafficking diseases including cystic fibrosis (CF) [4] [5] [6] [7] [8] [9] [10] [11] [12] . Some of these correctors function as pharmacological chaperones and bind directly to the mutant protein to improve its folding [10, 13] . Pharmacological chaperones for CF are predicted to be specific for the cystic fibrosis transmembrane conductance regulator (CFTR) and not correct other mutant proteins unless they share structural similarity with CFTR. Other correctors target cellular pathways and act through proteostasis [14] [15] [16] [17] [18] [19] . These proteostasis regulators are predicted to correct diverse protein trafficking diseases. The F508del-CFTR correctors chosen for this study include several structurally distinct compounds that act on different cellular pathways. They include the phosphodiesterase inhibitors KM57 and KM60 [18] , poly ADP-ribose polymerase (PARP) inhibitors ABT-888 [14, 20] and latonduine [15] , the cardiac glycoside ouabain [19] , the cyclooxygenase inhibitor glafenine [17] , carbamazepine, a sodium channel blocker which promotes proteasomal and autophagic degradation of mutant proteins [21, 22] , and RDR1, a corrector that we originally reported to act as a pharmacological chaperone [12] , but whose mechanism of action remains unclear [23] . We also included the F508del-CFTR pharmacological chaperone VRT-325 [10, 13] . Notably, VRT-325 has been reported to correct other mutated proteins besides CFTR [10] .
We investigated mutants from a diverse set of wellstudied protein trafficking diseases including the nephrogenic diabetes insipidus mutations V206D and L292P in the arginine-vasopressin receptor 2 (AVPR2, also known as V2R) [24, 25] , the LQTS2 mutations G601S and F805C in the human ether-a-go-go-related gene (KCNH2, also known as hERG) [26, 27] , and finally the persistent hyperinsulinemic hypoglycemia of infancy (PHHI, also known as congenital hyperinsulinism) mutations A116P and V187D in the sulfonylurea receptor 1 (ABCC8, also known as SUR1) [10, 28, 29] , a component of the K ATP channel. All these proteins are localized to the plasma membrane and have one or more glycosylation sites that can be used to monitor their progression through the secretory pathway by immunoblotting, where ER-retained (core-glycosylated) proteins migrate faster than rescued (complex-glycosylated) proteins. Additionally, there is currently no treatment for these diseases that addresses the basic protein trafficking defect.
We show that RDR1 rescues a mutant of the only other ATPase-binding cassette (ABC) protein related to CFTR in our study, SUR1. Additionally, we show that the phosphodiesterase inhibitors KM60 and KM57 rescue the trafficking of a hERG mutant. Finally, we show that ouabain modifies the glycosylation of all mutants tested, albeit without correcting the trafficking of proteins other than CFTR. Our results provide impetus for testing F508del-CFTR correctors on other trafficking disease mutants, which could generate new leads with therapeutic benefit to several rare diseases.
Methods

Cell lines and constructs
The GFP-tagged V2R WT clone was generated by sitedirected mutagenesis of plasmid V2R-V206D.GFP, kindly provided by Dr. Peter Deen (NCMLS, The Netherlands), using the primers 5 Chemiluminescent substrates were added and the blots were exposed to film.
Densitometry
The relative levels of each HERG glycoform for selected treatments were estimated by densitometry using Photoshop (Adobe Inc.). The values reported are expressed as means +/− SD (n = 3).
Patch clamping (hERG G601S)
Whole-cell currents were recorded from HEK hERG G601S cells after 48 h of treatment with compounds. An Alembic VE-2 patch clamp amplifier (Alembic Instruments Inc., Montreal) that provides full series resistance compensation was used to record whole-cell currents. The bath solution contained 137 mM NaCl, 4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose and 10 mM HEPES (pH 7.4). Patch pipettes were made from borosilicate glass with a resistance of 3-6 megaohms. Intracellular pipette solution contained 130 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 5 mM MgATP and 10 mM HEPES (pH 7.2). Cells were held at a potential of −80 mV. hERG tail currents were evoked by 4 s steps ranging from −60 to +50 mV in increments of 10 mV, with each step followed by a repolarizing step to -50 mV for 2 s. Data were collected and analyzed with Clampex 8 and Prism software.
Rubidium efflux (SUR1 mutants)
COSm6 cells were plated onto 6-well plates and transiently transfected with 0.6 μg SUR1 and 0.4 μg Kir6.2 plasmids and 3 μl Fugene overnight. The following day, the cells were treated with compounds or vehicle for 24 h. Cells were incubated for an additional 12 h in culture medium containing 86 RbCl (1 μCi/ml); during this period, compounds were present in the first 10 h followed by a 2-h washout. Rb + in the collected solution and the cell lysate was counted. The percentage efflux at each time point was calculated as the cumulative counts in the collected solution divided by the total counts from the solutions and the cell lysate.
Cyclic AMP assays
Cyclic AMP assays (Sigma-Aldrich) were performed according to the manufacturer's directions. Briefly, cells transfected with V2R plasmids were seeded at 3.0x10^5 cells/well in 24-well dishes and treated the following day for 24 h with compound, in quadruplicate. The following day, the cells were washed with warm PBS and treated with 250 μM IBMX for 10 min to inhibit any phosphodiesterase activity [33] . The medium was aspirated and replaced with either fresh medium containing 0.1% DMSO (unstimulated control, in duplicate) or fresh medium containing 100 nM DDAVP (stimulated, in duplicate) for 10 min to stimulate V2R at the cell surface [33] . Cells were washed with PBS and lysed in 110 μl of 100 mM HCl at room temperature. Supernatants were collected and centrifuged. 50 μl of the supernatant were used in the assay.
Statistical analyses
Statistical analysis was performed as described in the Figure legends. P-values < 0.05 were considered significant.
Results and discussion
We tested whether F508del-CFTR correctors could restore hERG G601S trafficking and function. As shown in Figure 1 , several correctors including KM57, KM60, glafenine, ouabain, and latonduine modified the glycosylation of this hERG mutant as judged by the appearance of slower-migrating, complex-glycosylated forms of the protein, indicating partial rescue. Treatment with glafenine, KM60 and KM57 resulted in the most prominent complex-glycosylated forms of HERG G601S, while latonduine treatment appeared to yield slightly less rescue. Low temperature, VRT-325 and the hERG channel blocker astemizole served as positive controls [10, 26] . Interestingly, low temperature treatment produced an additional slower migrating species that was not present in the other positive controls ( Figure 1A-E) . Treatment with the cardiac glycoside ouabain, a known inhibitor of trafficking of the wild type hERG channel [34] (see also Figure 2A ), produced an intermediate glycoform ( Figure 1B, Figure 3 ). Densitometric quantitation of some of the treatments is shown in Figure 1F . We also tested these correctors on the trafficking of the hERG F805C mutant. Unlike hERG G601S, the F805C mutant was only corrected by low temperature and an intermediate glycoform was produced with ouabain treatment (Figure 4) . Given that sildenafil, KM60 and KM57 are all phosphodiesterase inhibitors, and KM60 and KM57 were more potent correctors of hERG G601S, we chose to pursue only KM60 and KM57 in our study. To determine if correction resulted in a functional hERG G601S polypeptide, we used patch clamp recording ( Figure 5 ). A short (1 hr) washout of the correctors was necessary to observe an increase in hERG tail currents ( Figure 5 ). Exposure and washout of KM57 ( Figure 5C ), KM60 ( Figure 5D ), glafenine ( Figure 5E ), and astemizole ( Figure 5B ) all resulted in increased hERG G601S tail currents ( Figure 5F ). DMSO vehicle (0.1%) served as a negative control ( Figure 5A ). Treatment and washout of KM57 resulted in a statistically significant increase in hERG G601S tail currents above the DMSO control ( Figure 5F ). Since a washout step was necessary to observe tail currents, the mechanism used by these correctors may be through direct binding to, and inhibition of, the mutant channel [35] . Alternatively, KM57 and KM60 may be acting through a proteostasis regulator. To test this hypothesis, we used siRNA knockdown of PDE5A, the purported target of KM60 and KM57. Interestingly, knockdown of PDE5A did not result in an increase in hERG G601S trafficking ( Figure 2B ). Additionally, treatment of wild type hERG with these correctors reduced the amount of complex-glycosylated mature hERG detected by immunoblotting (Figure 2A ). In contrast, low temperature treatment of wild type hERG induced significantly greater amounts of both the core and complex-glycosylated forms of the protein, as would be expected due to the more favorable conditions for protein folding [19] . These results suggest that KM57 and KM60 may be acting through a proteostasis regulator other than PDE5A to affect hERG trafficking.
We next tested the SUR1 mutants V187D and A116P for correction with F508del-CFTR correctors. Treatment with several correctors yielded the complex-glycosylated form of these mutants, indicating partial rescue ( Figure 6 ). To determine whether correction of the SUR1 mutants leads to functional recovery of K ATP channels, we performed 86 
Rb
+ efflux assays to assess channel activity in intact cells in response to metabolic inhibition ( Figure 7) . In contrast to cells expressing wild type SUR1 protein, those expressing the SUR1 A116P mutant showed only low levels of channel activity due to loss of surface expression after treatment with the DMSO control. Exposing A116P-expressing cells to the reversible sulfonylurea drug tolbutamide for > 24 h followed by a washout 2 h prior to the assay led to almost complete recovery of channel activity, as reported previously [32] . Among the correctors Representative immunoblot for cells expressing V2R V206D treated with decreasing concentrations of ouabain (ouab), 10nM ABT-888, decreasing concentrations of RDR1 (RDR1), and glafenine (glaf) (A); ABT-888 (ABT), ouabain (ouab), KM60, and latonduine (Lat) (B); KM57 (C). Representative immunoblot for cells expressing V2R L292P treated with decreasing concentrations of ouabain (ouab), KM60, KM57, RDR1 (D); ABT-888 (ABT888), latonduine (Lat), and glafenine (E); carbamazepine (F). In all blots, lanes expressing vector controls (vector), and wild type V2R (wt) are shown. A line above the corresponding lanes indicates where V2R V206D or V2R L292P is expressed. Each blot has a vehicle control (DMSO or DMSO 0.1%) and a positive control (DMSO, 29°C). For V2R V206D, two other positive controls are also included (1% DMSO, glycerol). In (A-C), an arrow indicates core glycosylated V2R protein (core), a bracket indicates complex-glycosylated V2R protein (complex, indicating rescue), an arrowhead indicates nonglycosylated protein (nonglycosylated), and a star indicates GFP. In (D-F), a black arrow indicates mutant core glycosylated monomer, a black bracket indicates mutant complex-glycosylated monomer, and a black arrowhead indicates mutant dimer. The same symbols are also shown in gray to indicate the wild type V2R protein, which has a slightly slower mobility on SDS-PAGE. In all blots tubulin is shown as a loading control.
that enhanced the processing of A116P, KM57, KM60 and RDR1 were tested for their effects on functional recovery of the mutant channel. Only RDR1 improved channel function significantly (Figure 7 and data not shown). We previously reported RDR1 as a pharmacological chaperone for F508del-CFTR that binds to and stabilizes the first nucleotide-binding domain (NBD1) against thermal denaturation [12] . However, additional studies since then suggest that RDR1 does not exert its effect through NBD1 [23] , although RDR1 may act still as a pharmacological chaperone for F508del-CFTR by affecting other regions of the protein. Interestingly, sulfonylureas correct the trafficking of A116P and V187D mutants by binding to sites outside the affected domain in SUR1, and possibly also with a weak affinity site in Kir6.2 [36] . The mechanism of correction employed by RDR1 may be similar to that proposed for sulfonylureas, perhaps mediated by binding at a different site in SUR1. Alternatively, RDR1 may be acting as a proteostasis regulator through an unidentified protein that exerts its effects on both SUR1 and CFTR.
We also tested these correctors on the V2R mutants L292P and V206D (Figures 8 and 9 ). Although several correctors increased the trafficking of V2R V206D from ER to the Golgi compartment as evidenced by the appearance of complex-glycosylated forms of the protein ( Figure 8A-C) , none of them corrected V2R function following stimulation with a vasopressin analog (DDAVP) (Figure 9 ). The positive controls (1% DMSO and 29°C) increased cAMP production above the vehicle control with the V2R V206D mutant; however, this difference was A qualitative assessment of correction as determined by glycosylation status in immunoblotting is shown for each mutation following treatment with a corrector compound, where "-" indicates no correction observed, "+/−" indicates slight correction, "+" and "++" indicate more and best correction observed, respectively, and "ND" indicates not determined. Asterisks indicate that an intermediate glycoform was observed, but no correction. Astemizole and glibenclamide were included as positive controls for correction of hERG G601S and SUR1 mutants, respectively.
not statistically significant ( Figure 9A ). Cells expressing V2R L292P protein were slightly less amenable to correction by F508del-CFTR correctors than the V206D allele ( Figure 8D-F) . None of the correctors yielded functional correction upon stimulation ( Figure 9B) ; however, incubation at 29°C resulted in approximately 2-fold more cAMP than at 37°C ( Figure 9B ). This increase was not statistically significant. These results contrast with previously published results using COS cells where low temperature preincubation increased V2R function significantly [25] .
The lack of functional correction may be attributed to the use of different cell types, or to the mutant proteins not reaching the cell surface. This latter possibility seems less likely as recent work by Robben et al. shows that intracellular V2R can induce signaling in response to DDAVP stimulation [37] .
The results of immunoblotting studies are summarized in Table 1 . Only ouabain treatment altered the glycosylation of all mutants. RDR1 correction was the most protein-specific as it only corrected the trafficking of SUR1, the protein structurally related to CFTR in our test set [38] . However, the other correctors did appear to be partially allele-specific. They corrected at least one protein besides F508del-CFTR, but not necessarily both mutant alleles of the same protein.
Among the 9 correctors tested, only the cardiac glycoside ouabain altered the glycosylation of all mutant alleles for these three different ER-retained proteins. The only condition that corrects all mutant alleles is incubation at low temperature. Interestingly, when the transcriptional signatures of ouabain and low temperature are compared, they show significant overlap [19] , which may account for the altered glycosylation state of ER-retained mutant proteins. Although the exact mechanism employed by ouabain to elicit trafficking correction of F508del-CFTR has not been elucidated, it is known to inhibit the Na+/K + ATPase [39] . The inhibition of Na+/K + ATPase by ouabain leads to intracellular calcium fluctuations and altered glycosylation [40] , which, together, could allow ERretained proteins to escape ER-related protein quality control mechanisms. Except for F508del-CFTR, ouabain does not lead to functional correction of the two V2R trafficking mutants that we tested. This discrepancy might be due to the proteins escaping the ER, but not reaching the cell surface where they function. Alternatively, ouabain may not elicit enough correction for a functional response to be detected; suggesting that further optimization of its chemical scaffold or of the optimal dose would be necessary.
Conclusions
Taken together, the results provide a compelling case for testing novel F508del-CFTR correctors on mutated proteins in other trafficking diseases. Utilizing the hits identified in high throughput screens for correctors of F508del-CFTR can accelerate the development of correctors for the protein trafficking defect underlying other genetic diseases. A deeper understanding of the targets and mechanisms of action of proteostasis regulators will also be important in the development of these therapeutics.
